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The molecular mechanisms underlying hypothermic neuroprotection have yet to be
fully elucidated. Herein we demonstrate that global SUMOylation, a form of post-
translational modification with the Small Ubiquitin-like MOdifer, participates in the
multimodal molecular induction of hypothermia-induced ischemic tolerance. Mild (32◦C)
to moderate (28◦C) hypothermic treatment(s) during OGD (oxygen-glucose-deprivation)
or ROG (restoration of oxygen/glucose) increased global SUMO-conjugation levels and
protected cells (both SHSY5Y and E18 rat cortical neurons) from OGD and ROG-
induced cell death. Hypothermic exposure either before or after permanent middle
cerebral artery occlusion (pMCAO) surgery in wild type mice increased global SUMO-
conjugation levels in the brain and in so doing protected these animals from pMCAO-
induced ischemic damage. Of note, hypothermic exposure did not provide an additional
increase in protection from pMCAO-induced ischemic brain damage in Ubc9 transgenic
(Ubc9 Tg) mice, which overexpress the sole E2 SUMO conjugating enzyme and thereby
display elevated basal levels of global SUMOylation under normothermic conditions. Such
evidence suggests that increases in global SUMOylation are critical and may account for a
substantial part of the observed increase in cellular tolerance to brain ischemia caused via
hypothermia.
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INTRODUCTION
Stroke is the fourth leading cause of death and a lead-
ing cause of long-term disability in adults (Roger et al.,
2012). While a myriad of cellular and molecular brain injury
mechanisms have been reported in preclinical stroke models
(reviewed in Dirnagl et al., 1999; Mergenthaler et al., 2004;
Broussalis et al., 2012a), the individual targeting of these mech-
anisms has thus far not proven effective (reviewed in O’Collins
et al., 2006, 2009; Broussalis et al., 2012b). In the wake of
such failures ischemic brain damage has gradually become
viewed as a highly complex, multifactorial process that involves
the interplay of many non-dominant effectors (Hallenbeck
and Frerichs, 1993; Hallenbeck, 2002; Iadecola and Anrather,
2011).
In contrast to the aforementioned failures, hypothermia has
been recognized as perhaps the most robust brain cytoprotectant
studied in the laboratory to date (reviewed in González-Ibarra
et al., 2011; Yenari and Han, 2012). The neuroprotective effects
conferred by hypothermia are multifactorial. As such, hypother-
mia has been shown to alter a number of the pathologic molecular
mechanisms induced by cerebral ischemia. Such changes include
Abbreviations: SUMO, small ubiquitin-related modifier; OGD, oxygen-
glucose deprivation; ROG, recovery from oxygen/glucose deprivation; Ubc9,
ubiquitin conjugase 9; Tg, transgenic; pMCAO, permanent middle cerebral
artery occlusion.
reductions in metabolic and enzymatic activity, glutamate release
and re-uptake, inflammation, the production of reactive oxygen
species, and expression of various genes (reviewed in González-
Ibarra et al., 2011; Yenari and Han, 2012). Preliminary clinical
studies utilizing mild to moderate hypothermia as a treatment for
acute ischemic stroke are ongoing and results obtained thus far
have been encouraging (Macleod et al., 2010; van der Worp et al.,
2010; Abdullah and Husin, 2011; Kollmar et al., 2012). Despite
such work and the reproducible demonstrations of hypothermic
neuroprotection by a number of laboratories, the cellular and
molecular mechanisms underlying brain cytoprotection induced
via exposure to hypothermia are not fully understood.
One candidate capable of coordinating the multimodal
molecular mechanisms that underlie the cytoprotection induced
in the brain as a consequence of cooling is that of global
SUMOylation. Post-translational modification by this ubiquitin-
like modifier (ULM) appears to have multifunctional effects and
operates in states of tolerance to preserve homeostasis under
stress (Tempé et al., 2008). We have previously reported on the
massive increases in SUMOylation that occur in 13-lined ground
squirrels during hibernation torpor, a period in which their body
temperature declines to 5◦C (deep hypothermic condition) (Lee
et al., 2007). We hypothesized such massive increases in SUMO-
conjugation were involved in the profound natural tolerance to
the reductions in brain blood flow and oxygen delivery displayed
by these hibernating animals. Our work and that of others have
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shown that global SUMOylation is indeed involved in ischemic
tolerance in both in vitro cell culture systems (Lee et al., 2007,
2009; Datwyler et al., 2011; Cimarosti et al., 2012) and animal
models (Cimarosti et al., 2008; Yang et al., 2008; Lee et al., 2011).
SUMO, like ubiquitin, is synthesized as an inactive precursor
and subsequently processed by SUMO-specific proteases to
yield the mature di-glycine C-terminus. A single heterodimeric
E1 activating enzyme (SAE1/SAE2) initiates conjugation by
adenylating SUMO. This is followed by the formation of a
covalent thioester E1-SUMO intermediate. SUMO is then
transferred to the catalytic cysteine of the sole E2 conjugase, Ubc9
(Ubiquitin conjugase 9), which alone or in concert with an E3
ligase catalyzes the formation of an isopeptide linkage between
the C-terminal glycine residue of SUMO and the epsilon-amino
group of the substrate’s lysine residue. The conjugation actions
of Ubc9 are opposed by isopeptidases, which catalyze de-
SUMOylation thereby modulating steady state levels of SUMO-
conjugates (reviewed in Müller et al., 2001; Hay, 2005). There
are three systemically distributed SUMO paralogs in mammals:
the sequences of SUMO-2 and SUMO-3 are 96% identical and
are therefore difficult to distinguish. In contrast, SUMO-1 is only
45% identical with to the other two SUMO paralogs and has a
distinct immunoreactivity (Tatham et al., 2001).
Of note, we have generated Ubc9 transgenic (Ubc9 Tg) mice,
which displayed increased levels of SUMO-conjugation and an
improved tolerance to permanent middle cerebral artery occlu-
sion (pMCAO)-induced brain damage (Lee et al., 2011). Using
these Ubc9 Tg mice, the human neuroblastoma cell line SHSY5Y
and E18 derived rat cortical neurons, we present evidence that
strongly links hypothermia-induced ischemic resilience to corre-
sponding levels of global SUMOylation.
MATERIALS AND METHODS
SHSY5Y CELL CULTURE AND ISOLATION OF RAT CORTICAL
NEURONS/CULTURE
The human neuroblastoma cell line SHSY5Y (American Type
Culture Collection, Manassas, VA, USA) was cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, and
100 mg/ml streptomycin (DMEM complete) in 5% CO2 at 37◦C.
Embryos (day 18) of Sprague-Dawley rats were used to prepare
cortical neuronal cultures. Cortices were dissected from the
embryos, dissociated with papain (Worthington Biochemicals,
Lakewood, NJ, USA), and plated out at 1,000,000 cells per well
on poly-L-lysine-coated 6 well plates in Neurobasal-A/B27 media
(Lee et al., 2009). Cells were used after 7 days in culture.
OXYGEN AND GLUCOSE DEPRIVATION (OGD), RESTORATION OF
OXYGEN-GLUCOSE (ROG), HYPOTHERMIA, AND THE ASSESSMENT OF
CELL DEATH
Oxygen-glucose-deprivation (OGD) using SHSY5Y cells and cor-
tical neuronal cultures was performed as previously described
(Lee et al., 2007, 2009). OGD was carried out either at 37◦C
(normothermia) or 32◦C (hypothermia). After a 12 h (SHSY5Y)
or 3–9 h (cortical neurons) incubation, plates were taken out
of the OGD chamber, OGD media was replaced with com-
plete media which contained glucose (DMEM for SHSY5Y
and Neurobasal-A/B27 for cortical neurons), and incubated for
an additional 16 h at 37◦C (normothermia), 32◦C or 28◦C
(hypothermia) for restoration of oxygen/glucose (ROG).
Cell death as induced by OGD alone or after ROG was assessed
by nuclear staining with Hoechst 33342 and propidium iodide via
fluorescence-activated cell sorting (FACS) analysis as described
previously (Lee et al., 2007), or followed by counting directly
under the fluorescent microscope (Lee et al., 2009).
ANIMAL EXPERIMENTS
The National Institute of Neurological Disorders and Stroke Ani-
mal Care and Use Committee approved all experiments under
the protocol #1268-12 entitled “Use of Ubc9 Tg mice for pre-
clinical study of stroke.” Ubc9 Tg mice were generated as pre-
viously described (Lee et al., 2011). An equal number of male
and female adult mice (18–20 weeks old, weighing between
20–30 g) were used throughout the course of all experiments.
Of note, within this aged cohort males typically weighed more
than females, but brain sizes amongst males and females were
comparable and no significant gender differences in susceptibility
to pMCAO-induced brain damage were noted in the course of
our studies. Animal hypothermia was induced by using the water
immersion method described previously (Mou et al., 2013). Using
this method, body temperature was tightly controlled and we
noted that brain temperature (BT) was consistently recorded to
be 0.3–0.5◦C higher than the rectal temperature recorded during
hypothermic treatment. We therefore used rectal temperature
as a surrogate capable of monitoring BT. Animals were elimi-
nated from the study if any of the follow conditions were met:
(i) hemorrhage from the MCA; (ii) injury to another branch
of MCA; (iii) extreme cerebral blood flow change (i.e., <70%
and >90%); and (iv) inconsistent body temperature control
(surgery < 36.5◦C and >37.5◦C) + (hypothermia < 0.2◦C and
>0.2◦C of intended target temperature). The animals used in
these experiments were randomized and the surgeon was blinded
as to the genetic backgrounds of the animals. The evaluation
of infarct size was conducted in manner that blinded one to
both the experimental conditions and animal’s genetic back-
ground.
Oxygen saturation, heart and respiratory rates were monitored
using an Oximeter (STARR Life Sciences Corporation). Focal
cerebral ischemia was induced via pMCAO in mice as previously
described (Lee et al., 2011). Briefly, a 1.5∼2.0 cm incision was
made between the left eye and ear. A craniectomy was then per-
formed at the skull base (∼2 mm in diameter) to expose, cauterize
and transect the left MCA and it’s anterior branch (if available) at
the level of the olfactory tract. Of note, 24 h of a focal pMCAO
procedure will normally cause an infarct that occupies about one-
third of the ipsilateral hemisphere. As such, at 24 h after surgery
(unless otherwise described), each animal was anesthetized with
isoflurane and decapitated. Brains were promptly removed and
snap frozen for the assessment of brain damage and for Western
blot analysis of global SUMO-conjugation.
WESTERN BLOT ANALYSIS
The lysates from SHSY5Y cells or cortical neurons (Lee
et al., 2007, 2009) and brain extracts (Lee et al., 2007, 2011)
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were prepared as previously described. Rabbit polyclonal anti-
SUMO-1 and anti-SUMO-2/3 antibodies (both developed in-
house) and anti-β-actin antibody (Sigma Chemical) were used.
The intensities of bands were analyzed using Image-J (NIH).
In order to measure SUMO-conjugation levels, the region
corresponding to molecular weights 65 ∼300 kDa for cells
and ∼90 to 250 kDa for mouse brains in each lane were
cropped and the total intensity was analyzed (Lee et al.,
2007).
Cresyl VIOLET STAINING AND THE ASSESSMENT OF INFARCTION
VOLUMES
Frozen brain coronal sections (20 µm) from both WT and
Ubc9 Tg mice, which had undergone 24 h of pMCAO were stained
with cresyl violet; brain damage was subsequently assessed as
previously described (Lee et al., 2011). Briefly, quantification of
the infarct area was performed on 20 µm cresyl-violet-stained
sections collected at 0.34 mm intervals. The infarct area of each
section was measured using Image J. The effect of edema was
corrected for using the following equation (Leach et al., 1993):
corrected infarct area = infarct area × area of contralateral hemi-
sphere / area of ipsilateral hemisphere. Infarct volume (mm3) was
calculated for each animal by integrating the corrected infarct area
with the distance between sections (0.34 mm) (Arsenijevic et al.,
2006).
STATISTICS
Variables were analyzed (two group comparison) using a Mann-
Whitney U test with a Bonferroni correction. p< 0.05 was consid-
ered statistically significant. All values are expressed as a mean ±
SD (standard deviation) of at least three independent experiments
with at least 6 animals contained within each group. Correlations
between two variables of interest were obtained using Spearman’s
correlation coefficient. p < 0.05 was considered to be statistically
significant.
RESULTS
HYPOTHERMIA EXPOSURE INCREASES GLOBAL SUMO-CONJUGATION
LEVELS AND PROTECTS SHSY5Y CELLS AND RAT CORTICAL NEURONS
FROM OGD-INDUCED CELL DEATH
We examined whether mild (32◦C) to moderate (28◦C) hypother-
mia, both of which fall within the temperature range used to
induce clinical hypothermia, would be capable of increasing
SUMO-conjugation levels, and if so, would such an increase be
beneficial in an effort to protect cells from ischemic damage.
We first examined SHSY5Y cells for SUMO-1 conjugation levels
during OGD, or OGD/ROG at 37◦C, 32◦C, or 28◦C. As shown
in Figure 1A, 12 h OGD at 37◦C decreased SUMO-1 conjugation
(40% decrease from control), yet the decrease was much smaller
(less than 20%) when cells were subjected to OGD at 32◦C.
Of note, the levels of global SUMO-conjugation did not change
further when ROG was carried out at 37◦C, but the conjugation
levels significantly increased when ROG was carried out at either
32◦C or 28◦C. These results clearly indicate that hypothermic
treatments can both preserve during OGD and increase during
ROG the levels of SUMO-1 conjugation in SHSY5Y cells. As
shown in Figure 1B, 12 h of OGD at 37◦C resulted in ∼60%
FIGURE 1 | Hypothermia treatments during OGD and/or ROG increase
SUMO-1 conjugation levels and protect cells from OGD or
OGD/ROG-induced death in SHSY5Y cells. SHSY5Y cells were subjected
to OGD either at 37◦C or 32◦C for 12 h (a) followed by ROG at 37◦C (b) 32◦C
(c) or 28◦C (d) for 16 h. (A) SUMO-1 conjugation levels at each time point.
The upper panel is a representative immunoblot and the lower panel
presents a quantitation of SUMO-1 conjugation levels. Densities of higher
molecular weight conjugates (65 ∼ 300 kDa) were measured, normalized to
corresponding actin levels and shown as relative to control (neither OGD
nor ROG-treated cells). Data are presented as the mean ± SD of three
independent experiments. *p < 0.05 compared to normothermia during
ROG. (B) Cell death was assessed by nuclear staining with Hoechst 33342
and propidium iodide followed by fluorescence activated cell sorting (FACS)
analysis after OGD (a) or followed by ROG at 37◦C (b), 32◦C (c) or 28◦C (d).
Data are presented as the mean ± SD of three independent experiments.
*p < 0.05 compared to the normothermia group during ROG.
cell death, but the same length of OGD at 32◦C reduced cell
death to a mere ∼35%. Further, cell death induced by OGD
at 37◦C continue to increase following ROG at 37◦C to 70%,
but was significantly reduced (to ∼50%) when ROG was carried
out at 28◦C. As such, in line with previously published reports
hypothermic treatment inhibits cell death caused by either OGD
alone or OGD/ROG in SHSY5Y cells. Next, we carried out a simi-
lar set of experiments utilizing primary cultures of E18 rat cortical
neurons. We examined the effects of hypothermic treatment on
both global SUMO-1 conjugation levels and cell death during
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FIGURE 2 | Hypothermic treatments during ROG increase SUMO-1
conjugation levels and protect cells from OGD/ROG-induced death in
rat cortical neurons. Rat cortical neuronal cultures were subjected to OGD
at 37◦C for 3, 6 or 9 h followed by ROG at 37◦C (b) 32◦C (c) or 28◦C (d) for
16 h. (A) SUMO-1 conjugation levels at each time point: control, OGD alone
(a) and OGD/ROG (b: 37◦C, c: 32◦C, d: 28◦C). Representative immunoblots
(upper panel) and quantitation of SUMO-1 conjugation levels (lower panel).
Densities of high molecular weight conjugates (65 ∼ 300 kDa) were
measured, normalized to corresponding actin levels and shown as relative
to controls that did not receive an OGD or ROG exposure. Data are
presented as the mean ± SD of three independent experiments. (B) Cell
death was assessed by nuclear staining with Hoechst 33342 and propidium
iodide followed by counting directly under the fluorescent microscope
(≥300 cells) after OGD at 37◦C and ROG at 37◦C, 32◦C, or 28◦C. Data are
presented as the mean ± SD of three independent experiments. *p < 0.05
compared to normothermic OGD group.
ROG. Primary cortical neurons were subjected to OGD at 37◦C
for 3, 6, or 9 h, followed by ROG at 37◦C, 32◦C, or 28◦C. As shown
in Figure 2A, short durations of OGD increased SUMO-1 con-
jugation (i.e., preconditioning), but conjugation was drastically
decreased by longer/more lethal OGD. Of note, the SUMO-1 con-
jugation that was increased by shorter periods of OGD gradually
decreased during ROG at 37◦C. However, SUMO-1 conjugation
levels in these cells were restored and/or increased when ROG
was carried out under hypothermic conditions (32◦C or 28◦C).
In our experimental setting, 3 h of OGD followed by 16 h
of ROG resulted in a modest amount of cell death in cortical
neurons, and thus the protective effects of hypothermia were
minimal (Figure 2B). 6 h of OGD followed by 16 h ROG at
37◦C caused over 50% cell death in cortical neuronal cells, but
hypothermia treatment during ROG was capable of significantly
decreasing cell death (Figure 2B). 9 h of OGD was very severe
for the cortical neurons, yet hypothermic treatment during ROG
(especially at 28◦C) was capable of inducing significant protection
(Figure 2B).
WTMICE EXPOSED TO HYPOTHERMIA BEFORE pMCAO SURGERY
SHOWED ELEVATED SUMO-CONJUGATION LEVELS IN THE BRAIN AND
WERE PROTECTED FROM pMCAO-INDUCED BRAIN DAMAGE, WHILE
Ubc9 Tg MICE DISPLAYED NO ADDITIONAL PROTECTION AFTER
HYPOTHERMIC TREATMENT
We followed the hypothermic preconditioning paradigm that
was initially used in rats (Yunoki et al., 2003) for our mouse
experiments. In so doing, we compared WT mice with mice
that were transgenic for Ubc9, the sole E2 SUMO conjugase.
The hypothermic treatment paradigm employed is diagrammed
in Figure 3A: BT of WT and Ubc9 Tg animals was cooled to
28◦C over a period of 20 min, maintained at 28◦C for 20 min,
then increased to 37◦C over a period of 20 min, and finally
maintained at 37◦C for 20 min before the pMCAO surgery. The
BT of the normothermia group was kept at 37◦C for 80 min
under anesthesia before the pMCAO surgery. SUMOylation levels
throughout the entire brain were analyzed at each time point
during the hypothermic treatment. As shown in Figures 3B,C,
SUMO-1 and SUMO-2/3 conjugation levels in the brain were
increased when BT was maintained at 28◦C (stages 2–3). Of
note some of the increases persisted even when the BT was
returned to 37◦C (stage 4) in WT animals. The Ubc9 Tg mice
demonstrated trends similar to WT, yet the overall conjuga-
tion levels were predominantly higher than WT. Interestingly,
SUMO-1 (and SUMO-2/3) conjugation levels at stage 4, just
before pMCAO surgery, were essentially identical for WT and
Ubc9Tg mice. When hypothermia-pretreated WT mice were
subjected to pMCAO for 24 h, brain damage (infarction vol-
ume) was significantly less (∼50% reduction) as compared to
normothermic WT animals (Figure 3D). As reported in our
previous paper (Lee et al., 2011), Ubc9 Tg mice were more
resistant to pMCAO even under normothermic condition, and no
further reduction in brain damage was achieved via hypothermic
treatment (Figure 3D).
HYPOTHERMIC TREATMENT OF WT MICE AFTER pMCAO-SURGERY
ELEVATED SUMO-CONJUGATION LEVELS IN THE BRAIN AND
DECREASED pMCAO-INDUCED BRAIN DAMAGE, WHILE Ubc9 Tg MICE
THAT RECEIVED THE SAME TREATMENT PARADIGM DISPLAYED NO
FURTHER PROTECTION
In order to examine the effects of hypothermia on the pathologic
outcomes induced by the pMCAO surgery, animals (WT and
Ubc9 Tg) were subjected to surgery first after which their BTs
were maintained either at 37◦C, 32◦C or 28◦C for 2 h. Twenty
four hours later brains were harvested and ischemic damage
assessed. The treatment paradigm we employed is diagrammed
in Figure 4A. First, we examined the SUMO conjugation levels
in WT and Ubc9Tg brains at each time point (1–5). As shown
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FIGURE 3 | Effects of hypothermia exposure before pMCAO surgery on
brain SUMOylation levels and on subsequent pMCAO-induced
ischemic brain injury. (A) Diagram of serial temperature stages used
during hypothermic exposure of mice. Animals (WT and Ubc9 Tg) (1) were
cooled to 28◦C (BT) over a period of 20 min (2), maintained at a BT of
28◦C for 20 min (3), BT was increased to 37◦C over a period of 20 min
(4), and BT was maintained at 37◦C for 20 min before pMCAO surgery.
(B) Representative immunoblots for SUMO-1 conjugation (upper panel) and
SUMO-2/3 conjugation (lower panel) in whole brain extracts. At
time/temperature points 1–4, animals were euthanized and brains were
promptly removed and frozen for the Western blot analysis of SUMO
conjugation. Whole brain extracts were prepared and equal amounts of
protein (20 µg) were analyzed for SUMO conjugation. Actin levels were
also examined in the same blot. (C) Quantitative analyses of SUMO-1
conjugation (upper panel) and SUMO-2/3 conjugation (lower panel) at each
time point. Densities of higher molecular weight conjugates (90 ∼
250 kDa) were measured, normalized to the corresponding actin level and
shown relative to control (WT, without hypothermia). Blue: WT, and Red:
Ubc9Tg mice. Data are presented as the mean ± SD of 6 animals per
group (WT and Ubc9Tg) at each time point. (D) Hypothermia exposure
before pMCAO surgery significantly reduces pMCAO-induced infarction
volume in WT mice, but not in Ubc9 Tg mice. WT and Ubc9 Tg mice that
had been exposed to hypothermia and their normothermic control animals
in which brain temperatures had been maintained at 37◦C under anesthesia
for the same total duration as the hypothermia experimental groups
(80 min) were subjected to pMCAO, and 24 h later the brain infarction
volumes were measured. Blue: normothermia, Red: hypothermia. Data are
presented as the mean ± SD of 6 WT and 6 Ubc9 Tg animals in each of
the two conditions (normothermia and hypothermia). *p < 0.05 compared
to normothermia.
in Figures 4B,C, SUMO-conjugation levels (both SUMO-1 and
SUMO-2/3) in WT mice were significantly lower than those
in Ubc9Tg mice prior to pMCAO (stage 1, normothermia).
SUMO-2/3 conjugation, but not SUMO-1 conjugation in WT
mice, was increased by the pMCAO surgery (stage 2). SUMO-1
and SUMO-2/3 conjugation levels were slightly decreased or
unchanged during the recovery stage at 37◦C (stage 3) in WT
mice. Critically, when BTs were kept at either 32◦C (stage 4) or
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FIGURE 4 | Effects of hypothermia exposure after pMCAO surgery on
brain SUMOylation levels and pMCAO-induced brain injury.
(A) Diagram of hypothermia treatment protocol used in the mice. Animals
(WT and Ubc9 Tg) (1) were subjected to pMCAO surgery (2). After surgery
one group of WT and Ubc9 Tg animals had BTs maintained at 37◦C for
2 h (3) another group at 32◦C for 2 h (4), and a third group at 28◦C for
2 h (5) under anesthesia. All animals recovered from anesthesia and were
housed at room temperature with BTs equal to ∼37◦C for 24 h before
evaluating brain damage. (B) Representative immunoblots for SUMO-1
(upper panel) and SUMO-2/3 (lower panel) conjugation in the whole brain
extracts from WT and Ubc9 Tg mice. At each time point (1–5), 6 animals
in each group were euthanized, brains were promptly removed and frozen
for Western blot analysis. Whole brain extracts were prepared and equal
amounts of protein (20 µg) were analyzed for SUMO conjugation. Actin
levels were also examined in the same blot as loading controls.
(C) Quantitation of SUMO-1 (upper panel) and SUMO-2/3 (lower panel)
conjugation levels at each time point in WT and Ubc9 Tg. Densities of
higher molecular weight conjugates (90 ∼ 250 kDa) were measured,
normalized with corresponding actin levels and shown relative to controls
(WT with no pMCAO). Blue: WT, and Red: Ubc9 Tg. Data are presented as
the mean ± SD of 6 animals from the WT and from the Ubc9 Tg groups
at each time point. (D) Hypothermia exposure after pMCAO surgery
significantly reduces pMCAO-induced infarction volume in WT mice, but
not in Ubc9 Tg mice. Animals (WT and Ubc9 Tg) (18 animals from each
group) that had received pMCAO surgery were divided into 3 temperature
groups each with 6 WT and 6 Ubc9 Tg: one temperature group’s BTs were
maintained at 37◦C for 2 h; another at 32◦C for 2 h; and another at 28◦C
for 2 h under anesthesia. All animals recovered from anesthesia and were
housed at room temperature for 24 h and evaluated for brain infarct
volumes. Blue: 37◦C, red: 32◦C, green: 28◦C. Data are presented as the
mean ± SD of six of each animals (WT and Ubc9 Tg) group in each
condition. *p < 0.05; **p < 0.01.
28◦C (stage 5) after pMCAO surgery, SUMO conjugation levels
in WT mice were increased (stage 3 stage 4 < stage 5). SUMO
conjugation levels in Ubc9 Tg were generally higher than WT
(except SUMO-2/3 at stage 2) and were essentially unchanged by
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hypothermic treatment. Of note, under hypothermia, especially
at 28◦C, SUMOylation levels in both the WT and Ubc9 Tg mice
were effectively identical (Figures 4B,C). Next, we examined the
effect of hypothermia after pMCAO surgery on ischemic brain
damage. As shown in Figure 4D, hypothermic treatment (par-
ticularly at 28◦C) for 2 h after the surgery significantly reduced
brain damage in WT mice after pMCAO. In accordance with our
previous work Ubc9 Tg mice displayed much less ischemic brain
damage in the normothermic group, yet no gains in protection
were evident in the hypothermic groups (Figure 4D). We did
notice that brain infarction volumes in the 32◦C treated animal
groups (both WT and Ubc9 Tg) varied greatly. As such, we
analyzed the correlation of infarction volumes and SUMOylation
levels among these animals (6 WT, 6 Ubc9 Tg), and found
that infarction volumes did display a significant inverse linear
correlation with that of SUMO-1 conjugation levels (Spear-
man = −0.60839, P = 0.0358), and an inverse linear correlation
trend for SUMO-2/3 conjugation levels (Spearman = −0.56643,
P = 0.0548). These results provide evidence that hypothermia
exposure increases tolerance to brain ischemia in a manner
that is in direct proportion to its capacity to increase in global
SUMOylation.
DISCUSSION
The cytoprotective effects induced via elevated levels of SUMO-
conjugation have been reported in cell lines (Lee et al., 2007,
2009), primary neuronal cultures (Lee et al., 2009; Datwyler
et al., 2011; Cimarosti et al., 2012) and in the brains of
both rats (Cimarosti et al., 2008; Yang et al., 2008) and mice
(Lee et al., 2011). Increases in SUMOylation via hypothermic
treatments have been identified in hibernating ground squir-
rels (Lee et al., 2007), and were further noted in cell lines
(Lee et al., 2007), primary neuronal cultures (Loftus et al.,
2009; Wang et al., 2012) and rats (Yang et al., 2009; Wang
et al., 2012). Herein, we have shown that global SUMOyla-
tion is increased and sustained by both mild and moderate
hypothermia during OGD and ROG in both SHSY5Y cells
(Figure 1A) and rat cortical neurons (Figure 2A). It is pru-
dent to note that in those cells in which SUMOylation was
augmented by hypothermia, a concordant increase in toler-
ance to OGD and OGD/ROG-induced cell death was exhibited
(Figures 1B, 2B). It is therefore reasonable to deduce from both
our work and that of others that global SUMOylation may be one
of the molecular mechanisms underlying hypothermia-induced
ischemic neuroprotection.
To further explore this putative mechanism we used trans-
genic animals whose phenotype involves constitutively elevated
levels of global SUMOylation. Our Ubc9 Tg mice have been
previously phenotyped and the neuroprotection (post-focal brain
ischemia) afforded via the upregulation of SUMOylation in these
animals characterized (Lee et al., 2011). A myriad of different
experimental animal models for therapeutic hypothermia have
been reported (reviewed in Krieger and Yenari, 2004; Nagel
et al., 2008): each of which utilizes different depths, dura-
tions, and times of onset for hypothermia. Further, different
animals and models of stroke induction have been employed
(Evdokimov et al., 2008; Zhang et al., 2008). We performed two
sets of experiments: one using hypothermia as a precondition-
ing stress (i.e., hypothermic treatment before an ischemic chal-
lenge), and the other using hypothermia as a post-conditioning
stress (i.e., as a therapeutic intervention after an ischemic chal-
lenge). In so doing, we followed the hypothermic precondi-
tioning paradigm put forth by K.S. Lee’s group (Nishio et al.,
2000; Yunoki et al., 2002, 2003) for our mouse experiments.
By keeping the BT of WT mice at 28◦C for 20 min before
a pMCAO challenge (Figure 3A), SUMOylation levels in the
brain were shown to be increased (Figures 3B,C) while brain
damage was reduced significantly (Figure 3D). Ubc9 Tg mice
display baseline global SUMOylation levels higher than those
of WT and as such displayed a greater tolerance to pMCAO-
induced ischemic brain damage in the normothermic state than
WT mice (Lee et al., 2011). However, the Ubc9 Tg mice exhib-
ited no additional benefits from hypothermic preconditioning
(Figure 3D) which was in stark contrast to the WT mice. When
used in the post-occlusion period, hypothermia also showed
significant protection from pMCAO-induced brain damage in
WT animals, but not in Ubc9 Tg mice (Figure 4). Again, it is
prudent to note that both experimental paradigms could only
increase tolerance to brain ischemia if that exposure resulted in
a corresponding increase in global SUMOylation. These results
strongly suggest that global SUMOylation is an important mech-
anism in the induction of ischemic tolerance via exposure to
hypothermia.
Throughout the course of this study our Ubc9 Tg mice
demonstrated no additional gain in ischemic cytoprotection
from hypothermic treatment, which was in direct contrast to
what we witnessed in our WT controls. If SUMOylation is
indeed a critical component of the myriad of protective molec-
ular responses induced by hypothermia, Ubc9 Tg mice (which
have constitutively elevated levels of global SUMOylation even
under normothermic conditions) would be expected to fail in
displaying an increase in brain cytoprotection resultant from
hypothermic exposure to the same degree as WT mice. This
outcome is in line with our results and provides a direct link
between levels of SUMOylation and the litany of protective
molecular mechanisms underlying hypothermia-induced cyto-
protection post-ischemia. Unfortunately, SUMO-1,2,3 knock-out
animals are not yet available with which to investigate whether
SUMO-conjugation is an underlying molecular mechanism in
hypothermia-induce ischemic tolerance through a series of loss
of function experiments. While SUMO-1 knock-out mice have
been reported, the majority of SUMO-1 functions were com-
pensated for in vivo by SUMO-2 and SUMO-3 (Evdokimov
et al., 2008; Zhang et al., 2008). Similarly, when all three
SUMO isoforms are prevented from functioning via the over-
expression of a dominant negative Ubc9 mutant or by knock-
ing Ubc9 down in vitro cells are not capable of surviving
(Hayashi et al., 2002; Nacerddine et al., 2005; Lee et al.,
2007).
Among the many experimental stroke therapies hypothermia
remains one of the most effective and promising neuroprotectants
studied to date. However, several obstacles continue to impede
its clinical translation. As such, pharmacologically induced
hypothermia has been proposed as a very attractive alternative
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(Katz et al., 2004; Yenari et al., 2008; Choi et al., 2012). If
one considers that global SUMOylation may in fact be one of
the critical underlying mechanisms of hypothermia-induced
cytoprotection, the clinical utility in seeking ways to induce an
increase in global SUMOylation pharmacologically becomes
readily apparent. Accordingly, we are in the process of identifying
and aggressively pursing small molecules that increase global
SUMOylation via the high throughput screening of compound
libraries in an effort to advance neuroprotection and bring
effective molecular therapies to bear.
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